A股異動 | 基蛋生物漲停 2019年利潤總額同比增長38.34%
格隆匯2月13日丨基蛋生物(603387.SH)今日漲停,現報28.86元,暫成交6812萬元,最新總市值75億元。基蛋生物昨晚發公告稱,公司2019年度公司實現營業收入為9.7億元,比上年同期增長41.44%;營業利潤為3.99億元,比上年同期增長41.43%;利潤總額為3.97億元,比上年同期增長38.34%;2019年歸屬於上市公司股東的淨利潤為3.38億元,比上年同期增長35.58%;2019年度公司實現基本每股收益約為1.30元,比上年同期上升35.08%。此外據悉,基蛋生物曾在互動平台上指,控股子公司黃石醫養醫學檢驗有限公司已被湖北省衞生健康委員會列入“可開展新型冠狀病毒核酸檢測的第三方機構名單”中,已大量開展疫情相關的樣本檢測工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.